LDL receptor related protein 1BGenealiases: LRP-1B · LRP-DIT · LRPDIT
Q-omics provides the consensus-scored LRP1B profile across patient tissues and cancer cell-line models. LRP1B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LRP1B is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, LRP1B RNA expression shows 15,313 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, THCA, and THYM as cancer lineages where LRP1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRP1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRP1B survival associations across molecular data types. LRP1B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRP1B RNA expression–survival associations across cancer types. High LRP1B expression shows unfavorable associations in UCEC, KIRP, UVM and STAD, but favorable associations in BRCA and SCLC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for LRP1B RNA expression.
This table summarizes LRP1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and OV for protein.
This table ranks reproducible tumor–normal expression differences for LRP1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRP1B shows lower tumor expression in THCA, KIRC, KICH, COAD and BRCA and higher tumor expression in LUSC. The THCA box plot shows higher LRP1B RNA expression in normal versus tumor tissue (log2 FC = −3.635, t-test p < 0.001).
This table shows molecular features associated with LRP1B in patient tissues and cancer cell lines. In patient samples, LRP1B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRP1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
